GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Ticagrelor (Brilinta), oral tablet

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Brilinta - labeled renal guidance

Product / population
Ticagrelor (Brilinta), oral tablet
Renal method
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 56, posted Aug 07, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Brilinta - product and source limitations

Exposure and platelet inhibition observations in HD do not establish an outcome benefit in ESRD.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Brilinta - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Ticagrelor (Brilinta), oral tablet

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 56, posted Aug 07, 2026
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.7 Renal Impairment

Renal dysfunction alone does not require a ticagrelor dose change. Dialysis efficacy and safety outcomes were not established in the pivotal studies. Exposure and platelet inhibition observations in HD do not establish an outcome benefit in ESRD.

RDM74-brilinta-official-1 · Source locator: Renal guidance: 8.7 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 56, posted Aug 07, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
24fc224e24fbd2a10e274fb6dea09e7b8a86abbfd229671dbd1c6ca8895a6ded

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-brilinta&s1=RDM74-brilinta-official&h1=280b91e4a27cb637cb536dd68611af76c926f7ec271289ca200944bf2792273b

Top